Eli Lilly is facing a $183 million judgment for allegedly defrauding Medicaid by underreporting drug prices. The case highlights the complexity of Medicaid’s rebate system and raises concerns about the potential for unintended consequences for other regulated companies. The pharmaceutical giant is appealing the verdict, arguing that it adhered to its interpretation of the regulations.